	US 12,433,316 B2
	Compositions and methods for treatment of exocrine pancreatic insufficiency (EPI)
Rinat Ran-Ressler, Bridgewater, NJ (US); David Stephane Philippe, Auboranges (CH); and Jissy Jacob, Whitehouse Station, NJ (US)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 17/277,586
Filed by SOCIETE DES PRODUITS NESTLE S.A., Vevey (CH)
PCT Filed Sep. 20, 2019, PCT No. PCT/EP2019/075322 § 371(c)(1), (2) Date Mar. 18, 2021, PCT Pub. No. WO2020/058474, PCT Pub. Date Mar. 26, 2020.
Claims priority of provisional application 62/734,339, filed on Sep. 21, 2018.
Prior Publication US 2021/0352951 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A23L 33/12 (2016.01); A23L 33/00 (2016.01); A23L 33/125 (2016.01); A23L 33/17 (2016.01); A61K 9/00 (2006.01); A61P 1/18 (2006.01); A61P 5/48 (2006.01)

CPC A23L 33/40 (2016.08) [A23L 33/12 (2016.08); A23L 33/125 (2016.08); A23L 33/17 (2016.08)]

11 Claims

1. A method of treating exocrine pancreatic insufficiency (EPI), the method comprising administering to an individual in need thereof an effective amount of a nutritional composition having (1) a total protein consisting essentially of hydrolyzed protein and (2) a total fat comprising monoacylglycerols (MAG) that are at least about 30 wt % of the total fat, the total fat optionally further comprising medium chain triglycerides (MCT) and/or fatty acids, wherein the nutritional composition has an energy density of 1.0-2.0 kcal/ml.